CRUK Consent Forms – NET and Prostate Cancer Update

The regimen specific consent forms for neuroendocrine and adrenal cancers have been reviewed, updated and added to the CRUK website.

In addition, a new consent form for prostate has been added as well.

The forms can be found at www.cruk.org/sact_consent.

The new forms added to the neuroendocrine and adrenal cancer group are:

1. Fluorouracil, Carboplatin and Streptozocin (FCarboSt)
2. Gemcitabine and Capecitabine
3. Oxaliplatin, Irinotecan and Fluorouracil (FOLFOXIRI)
4. 177-Lutetium Dotatate

The new form added for prostate is:

1. Darolutamide – Docetaxel with ADT

Please share this update within your clinical teams or forward to the relevant lead cancer clinician for your organisation.

Any questions, please do let me know.

Best wishes,

Alia

Alia Nizam |Specialist Oncology Pharmacist. CRUK – Information Lead|